Inouye Eye Hospital, 4-3 Kanda-surugadai, Chiyoda-ku, Tokyo, 101-0062, Japan.
Nishikasai Inouye Eye Hospital, 3-12-14 Nishikasai, Edogawa-ku, Tokyo, 134-0088, Japan.
Jpn J Ophthalmol. 2024 May;68(3):206-210. doi: 10.1007/s10384-024-01052-8. Epub 2024 Apr 8.
To retrospectively evaluate the 3-year efficacy and safety of single-agent omidenepag isopropyl in patients with normal tension glaucoma (NTG).
Retrospective.
One hundred patients (100 eyes) who had newly been administered omidenepag isopropyl were enrolled in this study. Intraocular pressure (IOP) was compared at baseline and 6, 9, 12, 18, 24, 30, and 36 months after administration. The mean deviation values at baseline and 12, 24, and 36 months measured using the Humphrey visual field test (30-2 Swedish Interactive Threshold Algorithm standard) were compared. Adverse reactions and dropouts were assessed.
IOP significantly decreased from 15.5±2.7 mmHg at baseline to 13.8 ±2.3 mmHg after 6 months, 13.9± 2.3 mmHg after 12 months, 13.9±2.3 mmHg after 18 months, 13.8±2.1 mmHg after 24 months, 13.9±2.0 mmHg after 30 months, and 13.6±1.7 mmHg after 36 months (P < 0.0001). There was no significant difference in the mean deviation values at baseline (-3.66±3.49 dB), 12 months (-3.41±3.80 dB), 24 months (-3.13±3.81 dB), and 36 months (-3.06±3.30 dB). Adverse reactions occurred in 11 patients (11.0%), including conjunctival hyperemia in 6 patients. Fifty-two patients (52.0%) were excluded from the analysis because they discontinued treatment either due to IOP measurement by NCT or the use of additional drugs.
After the administration of omidenepag isopropyl, IOP in patients with NTG decreased within 3 years, visual fields were maintained, and safety was satisfactory. Thus, omidenepag isopropyl can be used as the first-line treatment for patients with NTG.
回顾性评估单药异丙基奥米登普用于正常眼压性青光眼（NTG）患者的 3 年疗效和安全性。
回顾性。
本研究纳入了 100 例（100 只眼）新接受异丙基奥米登普治疗的患者。比较给药前和给药后 6、9、12、18、24、30 和 36 个月的眼压。使用 Humphrey 视野计（30-2 瑞典交互阈值算法标准）测量的基线和 12、24 和 36 个月的平均偏差值进行比较。评估不良反应和脱落情况。
眼压从基线时的 15.5±2.7mmHg 显著下降至 6 个月时的 13.8±2.3mmHg、12 个月时的 13.9±2.3mmHg、18 个月时的 13.9±2.3mmHg、24 个月时的 13.8±2.1mmHg、30 个月时的 13.9±2.0mmHg 和 36 个月时的 13.6±1.7mmHg（P<0.0001）。基线时（-3.66±3.49dB）、12 个月时（-3.41±3.80dB）、24 个月时（-3.13±3.81dB）和 36 个月时（-3.06±3.30dB）的平均偏差值无显著差异。11 例（11.0%）患者出现不良反应，其中 6 例出现结膜充血。由于眼压测量或使用其他药物，52 例（52.0%）患者被排除在分析之外。
给予异丙基奥米登普后，NTG 患者的眼压在 3 年内下降，视野得到维持，且安全性令人满意。因此，异丙基奥米登普可作为 NTG 患者的一线治疗药物。
